- Conditions
- Moderate to Severe Chronic Plaque Psoriasis
- Interventions
- AbGn-168H, Placebo
- Biological
- Lead sponsor
- AbGenomics B.V Taiwan Branch
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Rogers, Arkansas • Ocala, Florida + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 1,765
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Norovirus Gastroenteritis
- Interventions
- VXA-G1.1-NN (high dose) Oral Vaccine Tablet, VXA Placebo Tablets, VXA-G1.1-NN (low dose) Oral Vaccine Tablet
- Biological · Other
- Lead sponsor
- Vaxart
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Crohn's Disease, IBD
- Interventions
- Brazikumab low dose, Brazikumab high dose, Humira®, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Lancaster, California + 31 more
- Conditions
- Burn, Pain, Dissociation, Opioid
- Interventions
- Ketamine, 0.9% NaCl
- Drug
- Lead sponsor
- University of Tennessee
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Covid19
- Interventions
- SCTA01, Placebo
- Drug · Other
- Lead sponsor
- Sinocelltech Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Somers Point, New Jersey
- Conditions
- Ulcerative Colitis
- Interventions
- Rosnilimab, Placebo
- Drug
- Lead sponsor
- AnaptysBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Garden Grove, California • Lancaster, California + 20 more
- Conditions
- Sickle Cell Disease, Vaso-occlusive Pain Episode
- Interventions
- L-citrulline, Placebo
- Drug · Other
- Lead sponsor
- Suvankar Majumdar
- Other
- Eligibility
- 4 Years to 21 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Hypercholesterolemia
- Interventions
- LY3015014, Placebo, Statin, Ezetimibe
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 527 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 15
- States / cities
- Encino, California • Lancaster, California • Spring Valley, California + 12 more
- Conditions
- Heart Failure
- Interventions
- Main cohort (Cohort A): Ponsegromab low dose, Main cohort (Cohort A): Ponsegromab medium dose, Main cohort (Cohort A): ponsegromab high dose, Main cohort (Cohort A): Matched placebo, Open-label, PK Cohort (Cohort B): ponsegromab low dose, Open-label, PK Cohort (Cohort B): ponsegromab medium dose, Open-label, PK Cohort (Cohort B): ponsegromab high dose, Optional Cohort C: Ponsegromab low dose, Optional Cohort C: Matched placebo, Optional Cohort D: Ponsegromab high dose, Optional Cohort D: Matched placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 455 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 22
- States / cities
- Fairhope, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 13 more
- Conditions
- Heart Failure
- Interventions
- Tolvaptan, placebo
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 99 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- QAX028, Tiotropium, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 4
- States / cities
- Anaheim, California • Normal, Illinois • Spartanburg, South Carolina + 1 more
- Conditions
- Obesity, Hypertriglyceridemia, Insulin Resistance, Hypertension
- Interventions
- Fish Oil, Flaxseed Oil, Placebo
- Dietary Supplement
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Ulcerative Colitis
- Interventions
- IV Tulisokibart, IV Placebo, SC Tulisokibart, SC Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 1,109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 76
- States / cities
- Dothan, Alabama • Fairhope, Alabama • Litchfield Park, Arizona + 65 more
- Conditions
- Venous Stasis Ulcer
- Interventions
- Erchonia ML Scanner (MLS), Placebo Laser
- Device
- Lead sponsor
- Erchonia Corporation
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Sarcopenia
- Interventions
- Rapamycin, Amino acid supplementation, Low-intensity resistance exercise, Sodium nitroprusside, Blood flow restriction cuff
- Drug · Other · Device
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 144 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Chemotherapy-induced Peripheral Neuropathy
- Interventions
- thrombomodulin alfa, Placebo
- Drug
- Lead sponsor
- Asahi Kasei Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 18
- States / cities
- Beverly Hills, California • Los Angeles, California • Norwich, Connecticut + 15 more
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment
- Interventions
- Placebo Comparator, insulin detemir
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Eosinophilic Esophagitis (EoE)
- Interventions
- Dupilumab, Matching Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 1 Year to 11 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 18 more
- Conditions
- Painful Diabetic Neuropathies
- Interventions
- Low Dose: 16 mg Engensis (VM202), High Dose: 32 mg Engensis (VM202), Control- Placebo (normal saline)
- Biological · Other
- Lead sponsor
- Helixmith Co., Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 13
- States / cities
- Walnut Creek, California • Orlando, Florida • Palm Beach Gardens, Florida + 9 more
- Conditions
- Obesity
- Interventions
- S-2367 Placebo, S-2367 1600 mg q.d. 54 Weeks, S-2367 1600 mg q.d. 60 weeks, LCD (low calorie diet), RCD (reduced calorie diet)
- Drug · Other
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 842 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 37 more
- Conditions
- Endometriosis Related Pain
- Interventions
- Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 623 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 41
- States / cities
- Andalusia, Alabama • Washington D.C., District of Columbia • Aventura, Florida + 36 more
- Conditions
- ADHD
- Interventions
- Methylphenidate, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 6 Years to 18 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Osteoarthritis, Knee
- Interventions
- Celution Device, Placebo
- Device · Other
- Lead sponsor
- Cytori Therapeutics
- Industry
- Eligibility
- 40 Years to 69 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 11
- States / cities
- Mesa, Arizona • Little Rock, Arkansas • La Mesa, California + 8 more
- Conditions
- Cocaine Use Disorders
- Interventions
- Lorcaserin, 10 mg, Lorcaserin, 20 mg, Oral Placebo
- Drug · Other
- Lead sponsor
- Midwest Biomedical Research
- Other
- Eligibility
- 21 Years to 50 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri